Vanda Pharmaceuticals Inc. (VNDA): Price and Financial Metrics

Vanda Pharmaceuticals Inc. (VNDA): $17.67

0.41 (+2.38%)

POWR Rating

Component Grades













Add VNDA to Watchlist
Sign Up

Industry: Biotech


of 505

in industry


  • VNDA scores best on the Value dimension, with a Value rank ahead of 98.64% of US stocks.
  • The strongest trend for VNDA is in Momentum, which has been heading down over the past 48 weeks.
  • VNDA ranks lowest in Momentum; there it ranks in the 5th percentile.

VNDA Stock Summary

  • VNDA's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 75.71 -- higher than 72.2% of US-listed equities with positive expected earnings growth.
  • The ratio of debt to operating expenses for Vanda Pharmaceuticals Inc is higher than it is for about just 9.85% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.17 for Vanda Pharmaceuticals Inc; that's greater than it is for just 11.12% of US stocks.
  • Stocks that are quantitatively similar to VNDA, based on their financial statements, market capitalization, and price volatility, are DIOD, SCWX, PCTI, CAMT, and DGII.
  • Visit VNDA's SEC page to see the company's official filings. To visit the company's web site, go to

VNDA Valuation Summary

  • In comparison to the median Healthcare stock, VNDA's price/earnings ratio is 21.37% lower, now standing at 28.7.
  • VNDA's price/sales ratio has moved NA NA over the prior 187 months.
  • Over the past 187 months, VNDA's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for VNDA.

Stock Date P/S P/B P/E EV/EBIT
VNDA 2021-08-31 3.6 1.9 28.7 20.9
VNDA 2021-08-30 3.6 2.0 29.0 21.1
VNDA 2021-08-27 3.7 2.0 29.6 21.6
VNDA 2021-08-26 3.6 1.9 28.5 20.7
VNDA 2021-08-25 3.6 1.9 28.7 20.9
VNDA 2021-08-24 3.5 1.9 27.6 20.1

VNDA Growth Metrics

  • The 5 year net income to common stockholders growth rate now stands at 161.25%.
  • Its 3 year price growth rate is now at 81.81%.
  • Its 5 year price growth rate is now at 12.19%.
VNDA's revenue has moved up $108,359,000 over the prior 52 months.

The table below shows VNDA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 258.529 56.886 32.44
2021-03-31 252.837 61.875 31.501
2020-12-31 248.168 51.775 23.337
2020-09-30 241.445 42.264 19.363
2020-06-30 240.622 38.888 113.839
2020-03-31 237.475 35.397 116.651

VNDA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VNDA has a Quality Grade of B, ranking ahead of 90.38% of graded US stocks.
  • VNDA's asset turnover comes in at 0.479 -- ranking 92nd of 677 Pharmaceutical Products stocks.
  • NEOG, SBBP, and AMGN are the stocks whose asset turnover ratios are most correlated with VNDA.

The table below shows VNDA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.479 0.904 0.105
2021-03-31 0.482 0.904 0.107
2020-12-31 0.486 0.906 0.086
2020-09-30 0.484 0.904 0.073
2020-06-30 0.493 0.900 0.085
2020-03-31 0.522 0.896 0.092

VNDA Price Target

For more insight on analysts targets of VNDA, see our VNDA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.00 Average Broker Recommendation 1 (Strong Buy)

VNDA Stock Price Chart Interactive Chart >

Price chart for VNDA

VNDA Price/Volume Stats

Current price $17.67 52-week high $21.86
Prev. close $17.26 52-week low $9.17
Day low $17.36 Volume 87,392
Day high $17.79 Avg. volume 463,691
50-day MA $16.97 Dividend yield N/A
200-day MA $16.92 Market Cap 983.12M

Vanda Pharmaceuticals Inc. (VNDA) Company Bio

Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. The company was founded in 2002 and is based in Washington, the District of Columbia.

VNDA Latest News Stream

Event/Time News Detail
Loading, please wait...

VNDA Latest Social Stream

Loading social stream, please wait...

View Full VNDA Social Stream

Latest VNDA News From Around the Web

Below are the latest news stories about Vanda Pharmaceuticals Inc that investors may wish to consider to help them evaluate VNDA as an investment opportunity.

Vanda (VNDA) Upgraded to Buy: Here's Why

Vanda (VNDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | September 21, 2021

Notable Vanda Pharmaceuticals Insider Trades $418.64 Thousand In Company Stock

Aranthan S. Jones Ii, Chief Corporate Affairs Officer at Vanda Pharmaceuticals (NASDAQ:VNDA), made a large buy and sell of company shares on September 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Aranthan S. Jones Ii purchased 12,119 Vanda Pharmaceuticals shares at prices ranging from $11.32 to $12.27 per share for a total of $141,250 on September 15. They then sold their shares on the same day in the open market.

Yahoo | September 17, 2021

Vanda Pharmaceuticals Announces Participation at the Citi 16th Annual BioPharma Virtual Conference

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda's management will participate at the Citi 16th Annual BioPharma Virtual Conference taking place between September 8 and September 10, 2021. Vanda management will host investor meetings. Vanda has updated its corporate presentation, which may be accessed on Vanda's website,, by clicking on the Investors tab and following the Corporate Presentation link.

Yahoo | September 8, 2021

Should Weakness in Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

It is hard to get excited after looking at Vanda Pharmaceuticals' (NASDAQ:VNDA) recent performance, when its stock has...

Yahoo | August 18, 2021

Novavax Names Jim Kelly CFO; Appoints Nasir Egal As SVP, Quality Assurance

(RTTNews) - Novavax, Inc. (NVAX) announced the appointment of Jim Kelly as Executive Vice President, Chief Financial Officer and Treasurer. Kelly joins Novavax from Supernus Pharmaceuticals, where he served as CFO. Previously, he was CFO and Treasurer at Vanda Pharmaceuticals. The company also appointed Nasir Egal as Senior Vice President,

Business Insider Markets | August 16, 2021

Read More 'VNDA' Stories Here

VNDA Price Returns

1-mo 2.26%
3-mo -13.13%
6-mo 17.64%
1-year 89.59%
3-year -23.01%
5-year 5.81%
YTD 34.47%
2020 -19.93%
2019 -37.20%
2018 71.91%
2017 -4.70%
2016 71.32%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 3.7762 seconds.